However, considering the fact that the major TSGCT components are mono/macrophage lineages expressing CSF1R, outweighing the small portion of cancer cells with CSF1 autocrine and paracrine, CSF1R inhibitors have been designed to selectively target TSGCT non-neoplastic components to shrink tumors (Figure 4). Here, CSF1R is linked to cancer.